GALT (galectintherapeutics.com) Net Profit

Official company branding of Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics (GALT) operations rely on a secure US clinical environment where developments are protected by humanitarian law and remain independent of foreign policy. Historical price action demonstrates that profit stands at -0.03. The business focuses on developing NASH therapies, which, upon successful approval, will grant the company exceptional pricing power within this free-market niche.

GALT (Galectin Therapeutics, Inc.) Company Net Income history from 07/04/2022 to 10/31/2026

Comprehensive metric breakdowns and analytics for galectintherapeutics.com (GALT)

- price and consensus price forecast:
Stock Quotes Galectin Therapeutics Inc.|GALT - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Galectin Therapeutics Inc.|GALT - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Galectin Therapeutics|GALT - Company Book Value|Market Value to Book Value Ratio galectintherapeutics.com|GALT - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Galectin Therapeutics|GALT - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Galectin Therapeutics Inc.|GALT - Company Aggregate Debts|Debts to Book Value Galectin Therapeutics Inc.|GALT - Company Long-Term Debt|Company Short-Term Loans and Borrowings Galectin Therapeutics|Critical Liquidity galectintherapeutics.com
- net income and valuation multiples indicators:
GALT - Net Profit
Fundamental valuation:GALT Galectin
Mass-produced product of Galectin Therapeutics Inc.

For Galectin Therapeutics (GALT), the company's bottom line reflects the efficiency of developing innovative drugs within a protected medical sector. This metric captures daily operating profit, measuring net cash flow after deducting all expenses. The trend of this indicator is sensitive to raw material and research costs, directly impacting final margins. Stable demand for biopharmaceuticals minimizes macroeconomic risks, making the asset a reliable tool for capital preservation.

Main competitors

Net Income Arrowhead Corp|MIRM (Mirum Pharmaceuticals) - Net Profit|Net Profit Dynavax Corp|Net Income ABUS (Arbutus Biopharma Corporation)|IVA (Inventiva SA) - Final Profit|Company Net Income Gyre Corp GYRE|Assembly Corp - Company Net Income|Genfit Corp - Net Profit|Net Financial Result DURECT Corporation DRRX|ALGS (aligos.com) - Net Income|BIVI (BioVie) - Company Net Income|GLMD (Galmed Pharmaceuticals Ltd) - Net Profit|Company Net Income ENDRA Corp NDRA|Company Net Income Hepion Pharmaceuticals (HEPA)